The Current Lung Cancer Neoantigen Landscape and Implications for Therapy.


Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
06 2021
Historique:
received: 12 11 2020
revised: 27 01 2021
accepted: 28 01 2021
pubmed: 14 2 2021
medline: 8 7 2021
entrez: 13 2 2021
Statut: ppublish

Résumé

All tumors harbor unique mutant peptides, some of which are able to elicit T-cell-mediated immune responses. These are known as neoantigens. Lung cancers bear a heavy mutational burden and hence many potential neoantigens. Neoantigens are increasingly recognized as key mediators of tumor-specific immune activation and have been identified as potential targets for personalized cancer therapies. In this review, we discuss the current data on neoantigens in lung cancer and provide an overview of the recent advances in neoantigen-based immunotherapy. Furthermore, we look ahead to highlight the major opportunities and challenges for the clinical application of neoantigen-based treatment strategies for thoracic and other malignancies.

Identifiants

pubmed: 33581342
pii: S1556-0864(21)01698-1
doi: 10.1016/j.jtho.2021.01.1624
pii:
doi:

Substances chimiques

Antigens, Neoplasm 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

922-932

Informations de copyright

Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Auteurs

Linda Ye (L)

National Centre for Asbestos Related Diseases, Faculty of Health and Medical Science, The University of Western Australia, Nedlands, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Australia. Electronic address: yang.ye@health.wa.gov.au.

Jenette Creaney (J)

National Centre for Asbestos Related Diseases, Faculty of Health and Medical Science, The University of Western Australia, Nedlands, Australia; Institute of Respiratory Health, The University of Western Australia, Nedlands, Australia; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia.

Alec Redwood (A)

National Centre for Asbestos Related Diseases, Faculty of Health and Medical Science, The University of Western Australia, Nedlands, Australia; Institute of Respiratory Health, The University of Western Australia, Nedlands, Australia.

Bruce Robinson (B)

National Centre for Asbestos Related Diseases, Faculty of Health and Medical Science, The University of Western Australia, Nedlands, Australia; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH